Follow
Oliver Sartor
Oliver Sartor
Verified email at tulane.edu - Homepage
Title
Cited by
Cited by
Year
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
JS De Bono, S Oudard, M Ozguroglu, S Hansen, JP Machiels, I Kocak, ...
The Lancet 376 (9747), 1147-1154, 2010
40032010
Alpha emitter radium-223 and survival in metastatic prostate cancer
C Parker, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fossĺ, ...
New England Journal of Medicine 369 (3), 213-223, 2013
37072013
Olaparib for metastatic castration-resistant prostate cancer
J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 382 (22), 2091-2102, 2020
17262020
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ...
New England Journal of Medicine 385 (12), 1091-1103, 2021
14582021
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402, 2016
13322016
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ...
Journal of Clinical Oncology 17 (11), 3461-3467, 1999
11441999
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
KR Carson, AM Evens, EA Richey, TM Habermann, D Focosi, JF Seymour, ...
Blood, The Journal of the American Society of Hematology 113 (20), 4834-4840, 2009
10532009
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
855*2018
Prostate specific antigen best practice statement: 2009 update
KL Greene, PC Albertsen, RJ Babaian, HB Carter, PH Gann, M Han, ...
The Journal of urology 189 (1), S2-S11, 2013
7062013
Radiation with or without antiandrogen therapy in recurrent prostate cancer
WU Shipley, W Seiferheld, HR Lukka, PP Major, NM Heney, DJ Grignon, ...
New England Journal of Medicine 376 (5), 417-428, 2017
6372017
Survival with olaparib in metastatic castration-resistant prostate cancer
M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 383 (24), 2345-2357, 2020
5852020
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind …
O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, ...
The Lancet Oncology 15 (7), 738-746, 2014
5602014
Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer.
CL Bennett, MR Ferreira, TC Davis, J Kaplan, M Weinberger, T Kuzel, ...
Journal of Clinical Oncology 16 (9), 3101-3104, 1998
5261998
Metastatic prostate cancer
O Sartor, JS de Bono
New England Journal of Medicine 378 (7), 645-657, 2018
5032018
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a …
P Hoskin, O Sartor, JM O'Sullivan, DC Johannessen, SI Helle, J Logue, ...
The Lancet Oncology 15 (12), 1397-1406, 2014
4832014
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline
IM Thompson, RK Valicenti, P Albertsen, BJ Davis, SL Goldenberg, ...
The Journal of urology 190 (2), 441-449, 2013
4632013
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ...
The Lancet Oncology 22 (7), 931-945, 2021
4412021
Prostate cancer–major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
MK Buyyounouski, PL Choyke, JK McKenney, O Sartor, HM Sandler, ...
CA: a cancer journal for clinicians 67 (3), 245-253, 2017
4152017
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities
SE Eggener, PT Scardino, PR Carroll, MJ Zelefsky, O Sartor, H Hricak, ...
The Journal of urology 178 (6), 2260-2267, 2007
4112007
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
O Sartor, RH Reid, PJ Hoskin, DP Quick, PJ Ell, RE Coleman, JA Kotler, ...
Urology 63 (5), 940-945, 2004
4112004
The system can't perform the operation now. Try again later.
Articles 1–20